Insulin therapy for type 2 diabetes – are we there yet? The d-Nav® story

Abstract Insulin replacement therapy is mostly used by patients with type 2 diabetes who become insulin deficient and have failed other therapeutic options. They comprise about a quarter of those with diabetes, endures the majority of the complications and consumes the majority of the resources. Ade...

Full description

Bibliographic Details
Main Author: I. Hodish
Format: Article
Language:English
Published: BMC 2018-04-01
Series:Clinical Diabetes and Endocrinology
Subjects:
Online Access:http://link.springer.com/article/10.1186/s40842-018-0056-5
id doaj-12bd75a7135443f78358429de1c0bd4c
record_format Article
spelling doaj-12bd75a7135443f78358429de1c0bd4c2020-11-25T00:29:52ZengBMCClinical Diabetes and Endocrinology2055-82602018-04-014111110.1186/s40842-018-0056-5Insulin therapy for type 2 diabetes – are we there yet? The d-Nav® storyI. Hodish0Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan Medical CenterAbstract Insulin replacement therapy is mostly used by patients with type 2 diabetes who become insulin deficient and have failed other therapeutic options. They comprise about a quarter of those with diabetes, endures the majority of the complications and consumes the majority of the resources. Adequate insulin replacement therapy can prevent complications and reduce expenses, as long as therapy goals are achieved and maintained. Sadly, these therapy goals are seldom achieved and outcomes have not improved for decades despite advances in pharmacotherapy and technology. There is a growing recognition that the low success rate of insulin therapy results from intra-individual and inter-individual variations in insulin requirements. Total insulin requirements per day vary considerably between patients and constantly change without achieving a steady state. Thus, the key element in effective insulin therapy is unremitting and frequent dosage adjustments that can overcome those dynamics. In practice, insulin adjustments are done sporadically during outpatient clinic. Due to time constraints, providers are not able to deliver appropriate insulin dosage optimization. The d-Nav® Insulin Guidance Service has been developed to provide appropriate insulinization in insulin users without increasing the burden on healthcare systems. It relies on dedicated clinicians and a spectrum of technological solutions. Patients are provided with a handheld device called d-Nav® which advises them what dose of insulin to administer during each injection and automatically adjust insulin dosage when needed. The d-Nav care specialists periodically follow-up with users through telephone calls and in-person consultations to bestow user confidence, correct usage errors, triage, and identify uncharacteristic clinical courses. The following review provide details about the service and its clinical outcomes.http://link.springer.com/article/10.1186/s40842-018-0056-5Insulin therapyHypoglycemiaDosageType 2 diabetes
collection DOAJ
language English
format Article
sources DOAJ
author I. Hodish
spellingShingle I. Hodish
Insulin therapy for type 2 diabetes – are we there yet? The d-Nav® story
Clinical Diabetes and Endocrinology
Insulin therapy
Hypoglycemia
Dosage
Type 2 diabetes
author_facet I. Hodish
author_sort I. Hodish
title Insulin therapy for type 2 diabetes – are we there yet? The d-Nav® story
title_short Insulin therapy for type 2 diabetes – are we there yet? The d-Nav® story
title_full Insulin therapy for type 2 diabetes – are we there yet? The d-Nav® story
title_fullStr Insulin therapy for type 2 diabetes – are we there yet? The d-Nav® story
title_full_unstemmed Insulin therapy for type 2 diabetes – are we there yet? The d-Nav® story
title_sort insulin therapy for type 2 diabetes – are we there yet? the d-nav® story
publisher BMC
series Clinical Diabetes and Endocrinology
issn 2055-8260
publishDate 2018-04-01
description Abstract Insulin replacement therapy is mostly used by patients with type 2 diabetes who become insulin deficient and have failed other therapeutic options. They comprise about a quarter of those with diabetes, endures the majority of the complications and consumes the majority of the resources. Adequate insulin replacement therapy can prevent complications and reduce expenses, as long as therapy goals are achieved and maintained. Sadly, these therapy goals are seldom achieved and outcomes have not improved for decades despite advances in pharmacotherapy and technology. There is a growing recognition that the low success rate of insulin therapy results from intra-individual and inter-individual variations in insulin requirements. Total insulin requirements per day vary considerably between patients and constantly change without achieving a steady state. Thus, the key element in effective insulin therapy is unremitting and frequent dosage adjustments that can overcome those dynamics. In practice, insulin adjustments are done sporadically during outpatient clinic. Due to time constraints, providers are not able to deliver appropriate insulin dosage optimization. The d-Nav® Insulin Guidance Service has been developed to provide appropriate insulinization in insulin users without increasing the burden on healthcare systems. It relies on dedicated clinicians and a spectrum of technological solutions. Patients are provided with a handheld device called d-Nav® which advises them what dose of insulin to administer during each injection and automatically adjust insulin dosage when needed. The d-Nav care specialists periodically follow-up with users through telephone calls and in-person consultations to bestow user confidence, correct usage errors, triage, and identify uncharacteristic clinical courses. The following review provide details about the service and its clinical outcomes.
topic Insulin therapy
Hypoglycemia
Dosage
Type 2 diabetes
url http://link.springer.com/article/10.1186/s40842-018-0056-5
work_keys_str_mv AT ihodish insulintherapyfortype2diabetesarewethereyetthednavstory
_version_ 1725329381052645376